QUOTE AND NEWS
StreetInsider.com  Oct 13  Comment 
Versar Inc. (NYSE: VSR) 48.6% HIGHER ; Ebola protective gear maker continues higher. VSR is a newly-discovered play on the theme. Codexis (NASDAQ: CDXS) 10% LOWER; profit taking after gaining 20% intra-day. Advanced Micro Devices, Inc....
SeekingAlpha  Aug 6  Comment 
Codexis, Inc. (NASDAQ:CDXS) Q2 2014 Earnings Conference Call August 6, 2014 4:30 PM ET Executives Ina McGuinness – IR Doug Sheehy – EVP, Chief Administrative Officer, General Counsel and Secretary John Nicols – President...
newratings.com  Jul 16  Comment 
VENLO (dpa-AFX) - Codexis Inc. (CDXS) touched a 52-week high of $2.65 on Tuesday before closing at $2.03 following the signing of a platform technology license agreement with GlaxoSmithKline (GSK). Accordingly, GSK has been granted a license to...
TheStreet.com  Jul 15  Comment 
NEW YORK (TheStreet) -- Codexis  soared to a 52-week high of $2.65 on Tuesday after the biocatalyst developer announced a technology licensing agreement with GlaxoSmithKline .  The deal grants GlaxoSmithKline a license to use Codexis'...
SeekingAlpha  Jul 15  Comment 
Codexis, Inc. (NASDAQ:CDXS) Corporate Conference Call July 15, 2014 8:30 AM ET Executives Douglas T. Sheehy – Secretary, Chief Administrative Officer and Executive Vice President John J. Nicols – President and Chief Executive...
StreetInsider.com  Jul 15  Comment 
Codexis (Nasdaq: CDXS) 41.8% HIGHER; announced the signing of a platform technology license agreement with GlaxoSmithKline (GSK). Under the terms of the agreement, Codexis granted GSK a license to use Codexis' proprietary CodeEvolver® protein...
SeekingAlpha  Jul 15  Comment 
Once the market opens, you can track how today's Stocks To Watch are performing here. To send in your own ideas for tomorrow's Stocks To Watch, email stockstowatch@seekingalpha.com before 6:00 AM ET Tuesday. Apollo Education Group...
newratings.com  Jul 14  Comment 
LONDON (dpa-AFX) - Codexis, Inc. (CDXS) said Monday that it has signed a platform technology license agreement with GlaxoSmithKline plc (GSK, GSK.L). Under the terms of the agreement, Codexis granted GlaxoSmithKline a license to use its...
SeekingAlpha  May 7  Comment 
Codexis, Inc. (CDXS) Q1 2014 Earnings Conference Call May 07, 2014, 04:30 PM ET Executives Douglas Sheehy - Executive Vice President, Chief Administrative Officer, General Counsel and Secretary John Nicols - President and Chief...
DailyFinance  Apr 17  Comment 
NEW YORK, NY -- (Marketwired) -- 04/17/14 -- LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Codexis, Inc....




 
TOP CONTRIBUTORS

Codexis (CDXS) (NASDAQ:CDXS) develops biocatalysts for manufacturing purposes in the pharmaceutical and biofuels industries. Biocatalysts are enzymes or microbes that stimulate or accelerate the chemical reaction. Many manufacturers have relied on naturally occurring biocatalysts, which has its inherent limitations, therefore Codexis provides biocatalysts to allow manufacturers to use them at anytime. The biocatatlysts can improve the manufacturing and commercialization processes for the pharmaceutical industry. In the biofuels industry, it uses biocatalysts to convert biomass into biofuels. [1]

The biocatalyst has specific advantages. Most chemical compounds for manufacturing cannot operate at room temperature, and biocatalyst uses simpler machinery. However there are limitations. Biocatalysts have not been stable enough to be used in industrial setings, therefore it is harder to scale and commercialize the product. Thus, there have been researchers attempting to use biotechnology to alter the genes in the biocatalysts, however there has not be any success to date. [1]

The company's initial public offering of stock filed on the NASDAQ exchange on 29 December 2009. The proposed offer price range is $13.00-$15.00. The company is offering 6.0 million shares and raising $84 million. [1]

For FY2009 with year ended 31 December 2009, the company reported $82.9 million in total revenue, up 64.2% from $50.5 million in total revenue for FY2008. Furthermore, the company had a net loss of $20.3 million in FY2009, an increase from a net loss of $45.1 million in FY2008. The revenues are distributed with 22% in product, 76% in related party collaborative R&D, 2% in collaborative R&D, and the rest in government grants. [1]

References

  1. 1.0 1.1 1.2 1.3 Codexis S-1/A
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki